rs7960917
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
rs8720
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<b>Materials & methods:</b> The rs8720 and rs7960917 in <i>KRAS</i> 3'UTR for colorectal carcinoma</span> (CRC) risk and survival were investigated in a case-control study.
|
31729889 |
2020 |
rs1137188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this case-control study of 371 CRC cases and 246 healthy controls, we analyzed the association between one SNP (rs1137188G > A) in the KRAS gene and four SNPs (rs3025039C > T, rs3025040C > T, rs3025053G > A and rs10434A > G) in the VEGF gene and CRC susceptibility by the improved multiplex ligase detection reaction (iMLDR) method.
|
28328959 |
2017 |
rs1137188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In genetic polymorphisms analysis, we found that the KRAS rs1137188 variant AA genotype had higher portion of tumor size (≥ 5 cm) (P = 0.01; Bonferroni-adjusted P = 0.04), which suggested that the rs1137188 variant AA genotype may significantly be associated with increased progression of CRC.
|
28328959 |
2017 |
rs397517040
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient.
|
24594115 |
2014 |
rs121913238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
23400451 |
2013 |
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In conclusion, minor allele of rs3025039, rs3212986, and rs712 polymorphisms increases the risk of CRC in the East Asian population, and heterozygote model of rs731236 polymorphism shows protective effect in the Middle East population.
|
31637880 |
2019 |
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Comparison of the data from patients with control group showed that polymorphism of rs712 in <i>KRAS</i> gene was protective factor, which was associated with susceptibility for CRC.
|
31156795 |
2019 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25).
|
23975373 |
2014 |
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer.
|
30568222 |
2019 |
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Biallelic mutations in MUTYH gene were detected in 3/12 (25%) remaining subjects with polyposis and in 6/90 (6.7%) patients with colorectal cancer (CRC) carrying KRAS p.G12C substitution, but not in 231 early-onset CRC cases negative for KRAS p.G12C allele.
|
29406563 |
2018 |
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion.
|
26056087 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.
|
30896620 |
2019 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of <i>KRAS</i> G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
|
31611389 |
2019 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, among the various <i>KRAS</i> mutations, that which encodes the G13D mutant protein (KRAS<sup>G13D</sup>) behaves differently; for unknown reasons, KRAS<sup>G13D</sup> CRC patients benefit from the EGFR-blocking antibody cetuximab.
|
31551296 |
2019 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS.
|
27805251 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far.
|
25367198 |
2014 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D).
|
18098337 |
2008 |